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phosphorylation. Systemic RG7116 exposure was greater 
than dose-proportional and total clearance declined with 
increasing dose, indicating that RG7116 elimination is 
target-mediated. This is consistent with the better efficacy, 
and the HER3 and pAKT inhibition, that was observed at 
doses >1 mg/kg. Tumor regrowth occurred from Day 46 
onwards and was associated with HER1 and HER2 upregu-
lation, indicating the activation of alternative HER escape 
pathways. Modulation of HER3 and phospho-HER3 was 
also demonstrated in the skin and mucosa of an RG7116-
treated cynomolgus monkey, suggesting that these may be 
useful surrogate tissues for monitoring RG7116 activity.
Conclusions These data confirm the promising efficacy of 
RG7116 and highlight the value of assessing the PK behav-
ior of the antibody and measuring target protein modulation 
as a marker of biological activity. Clinical development of 
RG7116 has now begun, and phase I trials are ongoing.
Keywords RG7116 · GE-huMab-HER3 · 
HER3 · Signaling inhibition · Pharmacokinetics · 
Pharmacodynamics
Introduction
The human epidermal growth factor receptor 3 (HER3/
ERBB3) is a 185-kDa member of the evolutionary-con-
served family of HER transmembrane receptors. Together, 
these four receptor tyrosine kinases form a dynamic sign-
aling network that transduces extracellular growth sig-
nals into the cell and activates multiple cellular pathways 
involved in proliferation, cell survival, and differentia-
tion. HER receptors normally exist as inactive monomers 
[1] and only become activated in response to overexpres-
sion or ligand binding followed by receptor dimerization. 
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glycoengineered antibody Fc moiety. We investigated the 
efficacy and pharmacokinetic/pharmacodynamic properties 
of HER3 signal inhibition by RG7116 in a murine xeno-
graft model of human head and neck cancer.
Methods SCID-beige mice bearing FaDu cells were 
treated with RG7116 at a weekly dose of 0.3–10 mg/kg, 
and tumor growth control and modulation of selected pro-
teins (HER3 and AKT) were examined.
Results Complete tumor stasis up to Day 46 was observed 
at a dose >3 mg/kg, and this dose down-modulated mem-
brane HER3 expression and inhibited HER3 and AKT 
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HER3 contains an extracellular neuregulin-binding 
domain, but unlike the other members of the HER family, 
it lacks an active intracellular kinase domain. Therefore, 
HER3 signaling is mediated through heterodimerization 
with other HER members. The HER2(ERBB2)/HER3 het-
erodimer is among the most stable of HER dimers and is 
a particularly potent initiator of phosphoinositide 3-kinase 
(PI3K) signaling [1]. Once activated, PI3K then trig-
gers the translocation of AKT to the phospholipid mem-
brane—through the second messenger PIP3—where AKT 
becomes phosphorylated and acts as a kinase for multiple 
substrates [2].
The role of HER1 (EGFR) and HER2 in tumorigenesis 
is well characterized, and multiple therapeutic compounds 
targeting these members of the HER family have now been 
developed. In contrast, less attention has been paid to the 
role of HER3 in human cancer. Elevated expression of 
HER3 is seen in many solid tumor types, and upregulation 
of HER3 is associated with poor outcome and reduced sur-
vival [3–8]. Indeed, HER3 may be required for the onco-
genic transformation of normal cells by other HER mem-
bers [9, 10]. Activated HER3 can interact directly with 
the p85 subunit of PI3K, whereas HER2 and HER1 can-
not [11]. Furthermore, upregulation of HER3 in response 
to therapeutic inhibition of other HER members is a rec-
ognized mechanism by which tumor cells can escape the 
action of HER1- and HER2-targeted therapies [12, 13]. 
Consequently, several antibodies targeting HER3 are now 
under investigation [14–21].
RG7116 is a novel humanized anti-HER3 therapeutic 
monoclonal antibody (mAb) with a dual mode of action. 
RG7116 binds selectively to domain 1 of HER3 with high 
affinity and effectively prevents binding of the HER3 
ligand, heregulin [22]. Binding of RG7116 to the extracel-
lular domain (ECD) of HER3 is characterized as a fully 
enthalpy-dominated key-and-lock mechanism, typical for a 
fully mature antibody–antigen interaction [23, 24]. HER3 
bound to RG7116 is maintained in the inactive, unliganded 
conformation, and the high stability of this complex effec-
tively prevents subsequent phosphorylation of HER3 and 
AKT phosphorylation in vitro. This translated into a potent 
inhibition of tumor cell growth in vitro, and robust efficacy 
in a variety of murine subcutaneous xenograft models of 
human cancer [22]. In addition to the therapeutic efficacy 
derived from HER3 signaling inhibition, RG7116 is glyco-
engineered for enhanced antibody-dependent cellular cyto-
toxicity (ADCC) [22].
In this study, we investigated the efficacy and pharma-
cokinetics (PK) of RG7116 treatment using a subcutaneous 
mouse xenograft model of human hypopharyngeal can-
cer. In addition, the expression of pharmacodynamic (PD) 




FaDu human hypopharyngeal squamous cell carcinoma 
cells (HER1 and KRAS wild type) were obtained from the 
American Type Culture Collection. Cell lines obtained 
from these suppliers are routinely authenticated by karyo-
typing, short-tandem repeat profiling, assessment of cell 
morphology, and species verification by isoenzymology. 
Cell lines were expanded upon receipt and aliquots fro-
zen. Cells were not passaged for more than 6 months after 
resuscitation. Tumor cells were routinely cultured in MEM 
medium supplemented with 10 % fetal bovine serum, 
2 mM l-glutamine, 1× NEAA, and 1 mM sodium pyru-
vate at 37 °C in a water-saturated atmosphere and 5 % CO2. 
Culture passage was performed with 0.05 % trypsin and 
0.02 % EDTA in phosphate-buffered saline every sixth–
seventh day. All reagents were obtained from PAN Biotech 
GmbH, Germany.
Xenograft model
FaDu cells (5.0 × 106 cells/mL) were injected subcutane-
ously under anesthesia into the right flank of female SCID-
beige mice (CB17.Cg-PrKdcscidLystbg; age 5–6 weeks at 
arrival; Charles River, Germany). After inoculation, FaDu 
xenograft tumors displayed rapid progressive growth 
(take rate 100 %) with an in vivo tumor doubling time of 
2–3 days. Mice were maintained under specific-pathogen-
free condition with daily cycles of 12-h light/12-h darkness 
according to the guidelines (GV-Solas; Felasa; TierschG) 
with food, and water was provided ad libitum. All animal 
experiments were conducted according to the guidelines 
of the German Animal Welfare Act and were approved by 
local government. Animals were examined daily for clini-
cal symptoms, detection of adverse effects, and assessment 
of body weight. Mice were randomized on Days 14–18 
when tumor volume was approximately 200 mm3 and treat-
ment started immediately.
Study FaDu_001: FaDu-bearing SCID-beige mice 
(n = 9–10/group) were randomized on Day 14 after inocu-
lation (mean tumor volume [TV] 150 mm3), and RG7116 
was administered at dose levels of 0.3, 1.0, 3.0, and 10 mg/
kg weekly ip on Days 14, 21, and 28. Serum was collected 
before the second (Day 21) and last treatment (Day 35) 
together with tumor (Day 35). Study FaDu_006: Mice were 
randomized on Day 17 (mean TV 220 mm3), and RG7116 
was administered as a single i.v. bolus dose at 0.3 and 
1 mg/kg on Day 18 (n = 35 mice/dose group; n = 15/con-
trol group). Serum and tumor were collected 1, 3, 6, 24, 96, 
168, and 240 h after RG7116 injection from five mice/time 
point/group (controls: 1, 96, 168 h). Study FaDu_008: 15 
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mice/group (mean TV 180 mm3) were randomized on Day 
18, and RG7116 was given weekly i.v. at 0.3 and 3.0 mg/kg 
on Days 18, 25, 32, 39, 46, 53, and 60 (or 3.0 mg/kg q3w 
on Days 18 and 39). Serum and tumor samples were col-
lected on Days 25, 32, and 39 (five mice/time point). The 
0.3 mg/kg dosing group was rechallenged with RG7116 at 
5 mg/kg on Days 39, 46, 53, and 60.
Assessment of anti-tumor efficacy
Tumor volume (TV) was measured by caliper twice-weekly 
beginning at randomization according to a standard for-
mula (TV = ½ length × width2); values were documented 
as means and standard error of the mean (SEM). Tumor 
growth inhibition (TGI) during the treatment period was 
calculated by comparing each treated group (treated) with 
its respective vehicle-treated control (resp. control) using 
the formula:
where TVday x represents the average tumor volume of a 
study group on study day x.
Data regarding tumor growth were analyzed using non-
parametric methods, since the data showed asymmetri-
cal behavior. Prior to this procedure, the data were base-
line-corrected with the tumor volume at the of the start 
treatment.
Pharmacodynamic analysis of the effect of RG7116 
on target modulation
Immunohistochemistry
Tissue was formalin-fixed and paraffin-embedded, and 
standard immunohistochemistry (IHC) was conducted 
using a murine mAb specific for HER3 (clone DAK-H3-IC, 
DAKO, #M7297) and rabbit mAb specific for phosphoryl-
ated HER3 (pHER3; clone 21D3, Cell Signaling Technolo-
gies, #4791). Staining was conducted using the DAKO 
autostainer (HER3) or Ventana Benchmark XT system 
(pHER3).
Western Blot analyses
Tissue was immediately lysed using Triton Lysis Buffer 
(1 % Triton-X-100; 10 µg/mL aprotinin; 0.4 mM orthova-
nadate; 1 mM phenylmethylsulfonyl fluoride), and lysates 
were denatured in NuPAGE Sample Reducing Agent at 
70 °C for 10 min. SDS–PAGE and Western blotting were 
conducted as described previously [22] using 20 μg protein 
TGI (%)
= 100−
TV(treated)day x − TV(treated)day y
TV(resp. control)day x − TV(resp. control)day y
× 100
per lane measured using a bicinchoninic acid assay and 
antibodies specific for HER1 (Upstate/Millipore, #06-847), 
HER2 (Dako, #A485), HER3 (clone C-17, Santa Cruz, #sc-
285), phosphorylated HER1 (pHER1, clone ID Y39; Epito-
mics/Abcam, #ab32086), or pHER3 (clone 21D3 [Tyr1289], 
Cell Signaling Technologies, #4791).
ELISA
Inhibition of AKT phosphorylation was examined in 
FaDu tumor lysates using the anti-phospho-AKT (pSer473) 
enzyme immune assay kit according to the manufacturer’s 
instructions (Enzo Life Sciences). Briefly, cell lysates and 
reference standards were incubated in wells coated with 
antibody specific for the amino terminus of AKT. Plates 
were washed and further incubated in biotinylated antibody 
specific for AKT phosphorylated at Ser473. After another 
wash, signal was detected using a solution of streptavidin-
HRP conjugate and tetramethylbenzidine substrate and 
quantified in a spectrometer at 450 nm. The amount of 
signal was directly proportional to the level of AKT 1/2 
pSer473 in the sample.
Gene expression profiling
A portion of tumor was preserved in RNAlater (Qiagen) for 
gene expression analysis. 50 ng of total RNA was ampli-
fied using the NuGen Ovation kit followed by labeling with 
the NuGen Encore kit. Gene expression profiling for HER1 
(232541_at) and ERBB2 (probe set 216836_s_at) was per-
formed on U133 plus 2.0 Genechips (Affymetrix). Preproc-
essing of the mRNA data was performed using the statistics 
software R (version 2.13.2), running in house scripts for 
quality control and data consolidation via the robust multi-
array average method.
Analysis of oral mucosa and skin in cynomolgus monkeys
Pharmacodynamic analyses in cynomolgus monkeys were 
conducted at Covance under standard operating proce-
dures and in compliance with applicable regulations about 
the use of laboratory animals. Skin and buccal mucous 
membrane biopsies were collected once before dosing i.v. 
20 mg/kg RG7116 and at approximately 2 and 6 h after 
dosing. A skin patch of approximately 1 g (approximately 
40 × 10 mm) was excised from the back, and a mucosal 
patch of approximately 0.5 g (approximately 25 × 7 mm) 
was excised from the buccal mucosa. Biopsies were per-
formed under ketamine and xylazine and cut into four 
pieces for further preparation. The wound was closed with 
surgical suture, and flunixin was given as antiphlogistic 
after biopsy. Samples were lysed, and HER3 levels were 
assessed by Western Blot or pHER3 IHC as described.
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Pharmacokinetic analysis of serum RG7116 levels
The concentration of RG7116 in mouse serum was meas-
ured using a generic human IgG ELISA (lower limit of 
quantification: 8 ng/mL) [25]. Serum concentration–time 
profiles were used to estimate the following PK parameters 
in mouse using non-compartmental analysis (WinNonlin, 
version 6.2; Pharsight Corporation, Mountain View, CA, 
USA): total drug exposure defined as area under the serum 
concentration–time curve extrapolated to infinity (AUCinf), 
total clearance (CLtotal), and observed maximum serum 
concentration (Cmax). A naïve pooled approach was used in 
mouse to provide one estimate for each dose group.
Results
RG7116 inhibits tumor growth in a dose-dependent manner 
in FaDu-bearing SCID-beige mice
The in vivo efficacy of single-agent RG7116 was evalu-
ated in a SCID-beige xenograft model bearing subcutane-
ous FaDu human head and neck cancer cells. This model 
was chosen to specifically investigate the inhibitory effect 
of RG7116 on the HER3 signaling pathway, as SCID-beige 
mice are severely immune-deficient; thus, the ADCC mode 
of action of RG7116 plays little or no role in these experi-
ments. FaDu xenografts express moderate levels of HER3 
but have a high pHER3/HER3 ratio. This was previously 
shown to correlate with efficacy with RG7116 [22]. Immu-
nohistochemical analysis identified high expression levels 
of membrane HER1 and medium expression of HER2 at 
baseline. To explore the effect of different RG7116 doses 
on tumor growth inhibition, RG7116 was administered 
to FaDu-bearing mice over a dose range of 0.3–10 mg/
kg (FaDu_001). Mice received three-weekly ip doses of 
RG7116 starting on Day 14 (Fig. 1a).
Growth inhibition was dose-dependent and reached a 
plateau between 3 and 10 mg/kg. Tumor stasis was sus-
tained for the duration of the study in animals treated with 
3 and 10 mg/kg RG7116 (Fig. 1b). Tumor growth was 
observed after the first administration in mice treated with 
0.3 mg/kg and after the third administration in mice treated 
with 1 mg/kg, albeit at a reduced pace compared to vehicle 
control mice.
Immunohistochemistry and Western blotting for HER3 
conducted in xenograft explants obtained at the end of 
the treatment (Day 35) showed that membrane HER3 
expression in tumors from mice treated with 1–10 mg/kg 
of RG7116 appeared to be downregulated compared to 
animals receiving 0.3 mg/kg RG7116 or vehicle control 
(Fig. 1c). All tested doses of RG7116 inhibited the phos-
phorylation of HER3 compared to controls, as seen by 
Western blotting (Fig. 1c): in mice treated with 0.3 mg/
kg RG7116, the level of pHER3 was reduced compared 
to control animals, whereas pHER3 was undetectable in 
explants from mice treated at doses above 1.0 mg/kg.
Assessment of RG7116 trough concentrations (Cmin) 
showed that mice administered a weekly dose of 0.3 mg/
kg did not exhibit serum RG7116 accumulation from the 
first to third administration (Fig. 1d); mean Cmin values 
were 1.66 and 1.48 µg/mL, respectively (Table 1a). A clear 
increase in mean Cmin from the first to third administra-
tion was seen in mice receiving weekly doses of 1, 3, and 
10 mg/kg RG7116 (Table 1a; Fig. 1d), indicating that target 
saturation as a surrogate of target-mediated drug disposi-
tion was being achieved from 1 to 10 mg/kg.
Pharmacokinetics and pharmacodynamics of RG7116 
following a single dose
To explore the PK and PD profiles following single-dose 
administration and to further understand the pharma-
cokinetic behavior with increasing dose, a second study 
(FaDU_006) was conducted in which RG7116 was admin-
istered as a single i.v. bolus dose at a less-efficacious 
(0.3 mg/kg) and an optimal efficacious (1 mg/kg) dose, 
based on the results of the first study (Fig. 2a). Systemic 
exposure (Cmax and AUC) increased with dose. However, 
the increase in exposure was higher than dose-proportional 
primarily for AUCinf (Table 1b). The total clearance (CLtotal) 
decreased with increased dose, going from 0.0312 to 
0.0232 mL/h, which is consistent with the faster elimina-
tion of RG7116 observed in the pharmacokinetic profile in 
the 0.3 mg/kg dose group (Fig. 2b).
The kinetics of pHER3 and HER3 inhibition following a 
single dose of RG7116 were investigated by Western blot-
ting in tumor explants obtained from mice killed at 1, 3, 6, 
and 24 h and 4, 7, and 10 days post-treatment. Data were 
standardized by calculating the ratio of pHER3 to HER3 
signal for each animal at each time point. Compared to 
controls, a maximum decrease in the mean pHER3/HER3 
ratio of 66.4 % (at 1 h) and 79.5 % (at 3 h) was seen fol-
lowing treatment with 0.3 and 1 mg/kg, respectively 
(Fig. 2c). The pHER3/HER3 ratio returned to within base-
line levels 96 h after treatment in mice treated with 0.3 mg/
Fig. 1  a Dose–response study (FaDu_001) investigating the effi-
cacy, pharmacodynamics, and pharmacokinetics of three-weekly ip 
doses of RG7116 (0.3–10 mg/kg) in female SCID-beige mice bear-
ing subcutaneous human hypopharyngeal cancer FaDu cells. b Dose-
dependent tumor growth inhibition was observed in mice treated with 
three doses of weekly RG7116. c Expression of HER3 and pHER3 
was down-modulated in mice receiving RG7116 at doses above 1 mg/
kg. d Accumulation of RG7116 was seen with doses above 1 mg/kg 
but not with the 0.3 mg/kg dose. IHC immunohistochemistry, SEM 
standard error of the mean, SD standard deviation
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kg RG7116, whereas inhibition of HER3 phosphorylation 
was maintained for longer in mice treated with 1 mg/kg, 
with the pHER3/HER3 ratio normalizing 240 h after treat-
ment. The higher dose of RG7116 also exerted a stronger 
inhibition on the downstream phosphorylation of AKT. 
Maximum reductions in pAKT of 47.8 and 63.6 % were 
observed 3 h after a single administration of 0.3 and 1 mg/
kg of RG7116, respectively (Fig. 2d).
An apparent inverse correlation between RG7116 expo-
sure and the pHER3/HER3 ratio was observed (Fig. 2e). 
After a single administration of 0.3 or 1 mg/kg RG7116, 
a rapid decrease in the pHER3/HER3 ratio was observed 
with a maximum mean decrease in ratio of 68.0 and 
79.0 %, respectively, with the pHER3/HER3 ratio return-
ing to baseline levels as serum RG7116 concentrations 
decreased. The pHER3/HER3 ratio returned to baseline 
values earlier in the 0.3 mg/kg treated group, consistent 
with the faster elimination seen in this group compared to 
mice treated with 1.0 mg/kg.
Extended dosing study of RG7116
To further investigate the scheduling and dose-/exposure-
related anti-tumor activity of RG7116 and target modula-
tion of HER3, an extended dosing study was performed 
(seven-weekly doses beginning on Day 18 after tumor 
implantation—study FaDu_008; Fig. 3a). A PK/PD tumor 
growth inhibition model (described elsewhere [26]) was 
used to guide the selection of the two doses investigated 
in this study. RG7116 was administered i.v. at an effica-
cious (3 mg/kg) and a less-efficacious dose (0.3 mg/kg). 
In addition, a group of mice were treated with a dose of 
3 mg/kg once every 3 weeks (q3w) to assess the schedule 
dependency.
As in the first study, RG7116 showed dose-dependent 
inhibition of tumor growth up to Day 39 (Fig. 3b). Mice 
treated with 0.3 mg/kg showed tumor growth after the first 
administration of RG7116, whereas mice treated at the 
higher dose showed tumor stasis for up to 3 weeks of treat-
ment. On Day 46, tumor regrowth was observed in mice 
from the 3 mg/kg groups until the end of the treatment 
(Fig. 3b).
Mice treated with 0.3 mg/kg of RG7116 were chal-
lenged with a higher dose of 5 mg/kg from Day 39 until 
the end of the treatment. This resulted in the inhibition of 
Table 1  RG7116 pharmacokinetic parameters in FaDu-bearing SCID-beige mice by non-compartmental analysis treated with (A) weekly 
administration of RG7116 and (B) a single dose of RG7116
Data are mean (CV %)
AUC, area under the curve; CLtotal, total clearance; Cmax, peak plasma RG7116 concentration; CV %, coefficient of variation; NM, not meas-
ured; PK, pharmacokinetics; t1/2, elimination half life
a
 Day since randomization/first dose. For all PK analyses, n = 5 mice were analyzed per time point
Study Dose (mg/kg) [no. of mice] Cmin (µg/mL)
Day 7a Day 14a Day 21a
(A) Weekly administration PK
FaDu_001 0.3 [n = 9] 1.66 (15.0) NM 1.48 (53.4)
1 [n = 10] 5.12 (23.8) NM 10.4 (21.2)
3 [n = 10] 17.8 (18.9) NM 36.7 (21.2)
10 [n = 10] 58.3 (13.0) NM 102 (24.1)
FaDu_008 0.3 [n = 15] 0.79 (25.3) 0.86 (55.8) 1.26 (52.0)
3 [n = 15] 8.88 (15.6) 13.5 (16.9) 17.6 (23.7)
Study Dose (mg/kg) [no. of mice] Cmax (µg/mL) AUCinf (haµg/mL) CLtotal (mL/h) t1/2 (h)
(B) Single-dose PK
FaDu_006 0.3 [n = 35] 2.55 192 0.0312 62.4
1 [n = 35] 9.73 863 0.0232 94.2
FaDu_008 3 [n = 15] 17.4 4811 0.0125 167
Fig. 2  a Pharmacokinetics and pharmacodynamics of RG7116 fol-
lowing a single i.v. administration of an efficacious (1 mg/kg) and 
less-efficacious (0.3 mg/kg) dose of RG7116 in FaDu xenograft 
mice (FaDu_006). b PK profiles for the two doses were similar until 
approximately 87 h post-dose, after which rapid elimination of anti-
body was seen with the lower dose. c Inhibition of pHER3 and pAKT 
(d) was seen with both doses initially; however, this was more pro-
longed with the efficacious dose. e An inverse correlation was seen 
between RG7116 exposure and both pHER3 and pAKT inhibition, 
with faster elimination in the 0.3 mg/kg group consistent with an ear-
lier return to baseline pHER3/HER3 levels. SD standard deviation
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tumor growth for two consecutive tumor assessments (from 
Day 39 to Day 50) after which FaDu tumor regrowth was 
observed from Day 53 onwards (Fig. 3b). No clear dif-
ference in tumor inhibition and regrowth was observed 
between mice treated with 3 mg/kg weekly compared to 
3 mg/kg q3w (Fig. 3b).
Again, no clear accumulation of RG7116 was observed 
with the lower dose (Table 1a; Fig. 3c). The apparent 
higher mean Cmin value observed after the third cycle of 
0.3 mg/kg RG7116 (1.26 µg/mL) was driven primarily by 
one mouse with higher than anticipated values. Follow-
ing the administration of 3 mg/kg, a clear increase in Cmin 
was observed (Table 1a; Fig. 3c). A full PK profile was 
obtained from mice treated with RG7116 3 mg/kg q3w, 
and a non-compartmental analysis was also conducted, 
which indicated that an increase in systemic exposure 
(AUCinf) was higher than dose-proportional from mice 
treated with 1 mg/kg (863 h*µg/mL—FaDu_006) to mice 
treated with 3 mg/kg (4,811 h*µg/mL—FaDu_008). This 
increase in AUCinf was accompanied by a further decrease 
in total clearance from 0.0232 to 0.0125 mL/h (Table 1b). 
Cmin values in study FaDu_008 were lower than those 
from mice treated with the same dose of RG7116 in study 
FaDu_001 (Table 1a). This may reflect the larger tumor 
volumes (and hence lower systemic exposure) seen in 
study FaDu_008 at baseline (mean 237 vs. 142 mm3 in 
study FaDu_001) and after 7 days of treatment (250 vs. 
161 mm3 in study FaDu_001).
The pHER3/HER3 ratio and level of pAKT were ana-
lyzed in mice killed 7, 14, and 21 days after starting treat-
ment with weekly 0.3 and 3 mg/kg RG7116 (represent-
ing animals receiving a total of one, two or three doses of 
RG7116, respectively). Assessment of biomarkers was also 
performed in animals killed 21 days after a single dose of 
3 mg/kg of RG7116 (representing a q3w dosing schedule). 
A clear difference in the pHER3/HER3 ratio was observed 
between mice treated with weekly 0.3 mg/kg RG7116 and 
3 mg/kg RG7116 (Fig. 3d). The pHER3/HER3 ratio was 
not decreased at any time point, following weekly admin-
istration of 0.3 mg/kg RG7116; however, a dramatic reduc-
tion in the pHER3/HER3 ratio was observed 7, 14, and 
21 days after initiation of weekly 3 mg/kg RG7116. Clear 
inhibition of pHER3/HER3 was also observed after seven 
and 14 days with RG7116 3 mg/kg q3w; a lower pHER3/
HER3 inhibition (~50 %) was observed by the end of the 
dosing interval (Day 21; Fig. 3d).
Similar to the pHER3/HER3 ratio, pAKT was not inhib-
ited by the end of the weekly dosing interval when mice 
received the lower dose of RG7116 (0.3 mg/kg; Fig. 3e). 
Mice receiving weekly doses of 3 mg/kg RG7116 showed 
reduced levels of pAKT after the first two cycles (−44.1 
and −37.9 %, respectively); however, by 21 days (after 
three administrations), suppression of pAKT inhibition was 
seen to diminish (−21.6 %; Fig. 3e). pAKT levels were ini-
tially reduced in mice receiving 3 mg/kg on a three-weekly 
cycle, but pAKT inhibition was diminished by 14 days 
after treatment initiation.
Tumor regrowth and HER1/HER2 escape
To investigate the cause of the tumor regrowth observed 
after Day 46 in mice treated with an efficacious dose of 
RG7116 (1 mg/kg qw; Fig. 3b), mRNA and protein levels 
of HER1 and HER2 were examined in a separate study. 
Treatment with RG7116 triggered a significant upregu-
lation of HER1 (~2.1-fold, p value 0.00014) and HER2 
(~1.3-fold; p value 0.0379) mRNA and HER1 (p value 
0.019) and HER2 (p value 0.036) protein levels compared 
to vehicle control, occurring as early as 4 days after dos-
ing with 1.0 mg/kg RG7116 (Fig. 3f). Western blot analysis 
on Day 52 (Day 39 in control mice) demonstrated that the 
expressed HER1 was phosphorylated in RG7116-treated 
mice, and inhibition of HER3 phosphorylation was main-
tained at this time point (Fig. 3g). HER2 and pHER2 levels 
were not changed (data not shown).
Exploratory pharmacokinetic and tumor growth assessment
In order to investigate the observed variability in response 
to RG7116 (seen primarily with the 0.3 mg/kg dose), an 
exploratory analysis of the relationship between tumor 
Fig. 3  a Extended dosing study investigating seven i.v. weekly 
administrations of an efficacious dose (3 mg/kg) and a less-effi-
cacious (0.3 mg/kg) dose of RG7116 in FaDu xenograft mice 
(FaDu_008). RG7116 given as a three-weekly cycle (two doses in 
total) was also investigated. b Dose-dependent efficacy up to Day 39 
was seen as in the previous study and tumor growth inhibition with 
3 mg/kg RG7116 given as a three-weekly cycle was similar to weekly 
dosing. Mice in the 0.3 mg/kg group were rechallenged (black arrow) 
with 5 mg/kg on Day 39 resulting in tumor growth inhibition for two 
further assessments; however, tumor regrowth was observed in all 
dosing groups from Day 50. c RG7116 trough concentrations from 
the first to third administrations again showed accumulation only with 
the higher dose. Inhibition of HER3 (d) and AKT (e) phosphoryla-
tion was also seen with weekly dosing at the efficacious dose (3 mg/
kg) but not with the lower dose (0.3 mg/kg). Following a single 3 mg/
kg dose (representing a three-weekly schedule), initial inhibition 
of HER3 phosphorylation was seen to diminish by Day 14 and 21. 
f Upregulation of HER1 (~2.1-fold) and HER2 (~1.3-fold) mRNA 
was seen 96 h after FaDu xenograft mice (n = 5) were administered 
1.0 mg/kg RG7116 in a separate study, and this was associated with 
upregulation of HER1 and HER2 protein. g To compare the sin-
gle animals, 20 µg total protein lysate was loaded per lane (lanes 
101–110 are vehicle and 201–210 are the RG7116-treated animals). 
At Day 52, inhibition of HER3 phosphorylation was maintained in 
RG7116-treated mice, and expressed HER1 was seen to be phos-
phorylated compared to vehicle control. HER2 and pHER2 were not 
changed (data not shown). SEM standard error of the mean, SD stand-
ard deviation
◂
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volume and RG7116 serum concentrations after three 
administrations was performed using five mice per group 
(Fig. 4a, b for study FaDu_001 and FaDu_008, respec-
tively). A trend was observed between tumor volume and 
RG7116 exposure in both studies. After three adminis-
trations, tumor volumes in animals with higher RG7116 
serum exposures tended to be within baseline tumor vol-
ume ranges, whereas mice achieving lower serum RG7116 
exposure tended to have larger tumors. Interestingly, one 
mouse in each study treated with the lowest dose tested 
(0.3 mg/kg) also showed tumor volumes after 3 weeks of 
treatment within baseline ranges, comparable with mice 
treated with the highest doses tested in each study. These 
two mice had the lowest baseline tumor volumes in each 
of the studies (48.6 and 73.0 mm3 for FaDu_001 and 
FaDu_008, respectively). Comparison of the effect on 
tumor growth in mice with the largest and smallest baseline 
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Fig. 4  Tumor growth control following three-weekly administrations 
of RG7116 correlated with RG7116 exposure. In mice achieving 
higher serum exposure of RG7116 after 3 weeks of RG7116 treat-
ment, tumor volume tended to reduce to baseline ranges (dotted lines) 
compared to other mice (a study FaDu_001 and b study FaDu_008). 
In each study, a high level of tumor growth control was observed in a 
mouse receiving the lowest (0.3 mg/kg) dose (black arrows). These 
mice had the smallest baseline tumor volumes in each of the stud-
ies (c, d). Comparison of the tumor growth control rate afforded by 
0.3 mg/kg in the mice with the smallest and largest baseline tumor 
volumes in study FaDu_001 (c) and FaDu_008 (d)
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d for studies FaDu_001 and FaDu_008, respectively. Nota-
bly, tumor growth in control-treated mice was not depend-
ent on baseline tumor volume; all tumors progressed 
rapidly. While tumor stasis was achieved with 0.3 mg/kg 
RG7116 in mice with the smallest baseline tumors in both 
studies, only partial tumor growth control was achieved at 
this dose in the mouse with the largest baseline tumor vol-
ume (217 mm3) in study FaDu_001 (Fig. 4c). Interestingly, 
in FaDu_001, the mouse with the smallest baseline tumor 
showed an accumulation of RG7116 serum levels from the 
first administration (Cmin = 1.94 µg/mL) to third adminis-
tration (Cmin = 2.67 µg/mL). However, the mouse with the 
largest baseline tumor volume did not show RG7116 accu-
mulation levels during the dosing period (Cmin = 1.44 µg/
mL after first administration and Cmin = 1.50 µg/mL fol-
lowing third administration). In study FaDu_008, the 
mouse with the largest baseline tumor volume (312 mm3) 
showed a tumor growth profile similar to the mean tumor 
growth profile from the mice treated with vehicle control 
(Fig. 4d), whereas the mouse with the smallest baseline 
tumor achieved tumor stasis during the length of the study. 
Similarly to mice in study FaDu_001, the mouse with the 
smallest baseline tumor showed higher Cmin (1.62 µg/mL) 
21 days after the start of dosing, whereas the mouse with 
the largest baseline tumor showed lower Cmin (0.32 µg/mL).
Expression of HER3 and pHER3 is modulated in skin 
and oral mucosa
As a surrogate approach, the ability to assess the effects 
of a therapeutic compound in tissue biopsies that are more 
easily accessible than the tumor would greatly facilitate 
future drug development and the assessment of pharma-
codynamic effects in patients. Therefore, the potential for 
using oral mucosa and skin as surrogate tissues for phar-
macodynamic marker analysis was investigated in a sin-
gle cynomolgus monkey. This study used a higher dose 
(20 mg/kg) of RG7116 than was used in the murine mod-
els to ensure that both HER3 inhibition and 100 % target 
saturation were achieved. Following a single treatment with 
20 mg/kg RG7116, the level of HER3 detected by Western 
blotting was dramatically reduced in mucosa and skin biop-
sies taken 2 and 6 h post-dose, compared to pretreatment 
levels (Fig. 5a). Expression of pHER3 in skin as meas-
ured by IHC was also markedly reduced (Fig. 5b) and was 
barely detectable at 6 h.
Discussion
RG7116 is a novel anti-HER3 antibody that can exert a 
therapeutic effect through both the inhibition of HER3 
signaling and by recruiting immune effector cells for 
ADCC [22]. In order to better understand the therapeutic 
potential of RG7116, we further assessed the anti-tumoral 
efficacy mediated by HER3-signaling inhibition in a FaDu 
cell line-based xenograft of human hypopharyngeal can-
cer and characterized the PK and PD changes occurring in 
response to treatment with RG7116 at different doses and 
dosing schedules.
RG7116 showed nonlinear PK in mice with rapid 
serum clearance at low doses (0.3–1 mg/kg) and slower 
clearance at higher doses (3 mg/kg). Systemic exposure 
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Fig. 5  Down-modulation of HER3 and inhibition of HER3 phospho-
rylation in surrogate tissues. a Compared to baseline, levels of HER3 
were markedly diminished in oral mucosa and skin biopsies at 2 and 
6 h post-treatment in a cynomolgus monkey treated with 20 mg/kg 
RG7116. b IHC shows expression of pHER3 in skin tissue and was 
also reduced following treatment. (IHC was scored from 0 to +++; 
+ to ++ indicates positive staining and 0 to + indicates borderline/
negative staining)
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accompanied by a decline in total clearance with increas-
ing dose, indicating that elimination of RG7116 is target-
mediated [27]. Maximal efficacy was seen at doses ≥3 mg/
kg, consistent with the slower clearance observed at that 
dose. In addition, the lack of RG7116 Cmin accumulation 
following chronic administration of 0.3 mg/kg indicates 
a predominant involvement of target-mediated clearance 
resulting in suboptimal efficacy. Accumulation of RG7116 
in serum was observed with doses from 1 to 10 mg/kg in 
study FaDu_001 and following 3 mg/kg administration in 
study FaDu_008. This distinct exposure pattern was con-
sistent with the improved efficacy and greater decrease 
in the pHER3/HER3 ratio seen with higher doses, and is 
likely due to the target saturation. In addition, the PK pro-
file of RG7116 was correlated with the pHER3/HER3 ratio 
profile following single-dose administration, with the faster 
elimination shown in the lower dose group (0.3 mg/kg) 
being consistent with an earlier return of pHER3/HER3 to 
basal levels.
This cell line-based tumor model is characterized by a 
rapid and progressive tumor growth in vivo indicated by 
a short tumor doubling time of 2–3 days. Therefore, rand-
omization is done between Days 14 and 18 with individual 
variability, and control-treated animals have to be excluded 
early on, as is often seen with other models. Despite these 
model imitations, the anti-tumor efficacy induced by 
RG7116 in the FaDu xenograft model was strong and dose-
dependent in both multiple treatment studies and consist-
ent with previous data [22]. Efficacious doses of RG7116 
also inhibited HER3 phosphorylation and down-modulated 
membrane HER3 expression in explanted tumor tissue in a 
similar manner as reported previously. Furthermore, dose-
related downstream inhibition of pAKT was also observed. 
In all studies, the 3 mg/kg dose appeared to be optimal for 
the FaDu subcutaneous xenograft model system investi-
gated. At this dose level, tumor stasis was achieved with 
weekly RG7116 in both multiple dosing studies, and tar-
get modulation was observed. No difference in efficacy 
was seen between the 3 and 10 mg/kg doses, suggesting 
that higher doses do not appear to offer further benefit. A 
lesser degree of tumor growth inhibition was seen with a 
suboptimal dose (0.3 mg/kg); however, rechallenging mice 
treated at this level with a higher dose (5 mg/kg) appeared 
to restore anti-tumor efficacy. Efficacy with 3 mg/kg given 
weekly was similar to that of 3 mg/kg given on a 3-week 
cycle. However, pHER3/HER3 was only ~50 % inhibited 
by the end of the q3w dosing interval (day 21). Further 
work is required to understand the extent of pHER3/HER3 
inhibition required to achieve efficacy.
Despite initial tumor stasis, tumor regrowth was 
observed in mice treated once-weekly with 3 mg/kg 
RG7116 after approximately 46 days. This escape from 
RG7116-induced growth inhibition was associated with 
upregulation of both HER1 and HER2. Therefore, two rea-
sons for failure to control tumor growth with RG7116 were 
observed: suboptimal dosing and activation of alternative 
signaling pathways involving HER1/2. Combined inhibi-
tion of HER3 and other members of the HER family is an 
attractive option for enhancing the efficacy of RG7116. The 
availability of potent mAb inhibitors of individual members 
of the HER family will allow for a personalized medicine 
approach in the clinic, with appropriate antibodies selected 
based on the HER profile of the patient’s tumor. This could 
also imply that a detailed molecular characterization of 
the tumor needs to be addressed at the time of progression 
to overcome bypass mechanisms. We previously demon-
strated that combining RG7116 (anti-HER3 antibody) with 
RG7160 (anti-HER1 antibody) or pertuzumab (anti-HER2) 
achieved complete and long-lasting tumor growth inhibi-
tion in murine subcutaneous xenograft models in which 
tumor growth was driven by HER1 or HER2, respectively 
[22].
Inhibition of HER3 signaling alone was insufficient 
to control tumor growth in the immune-deficient mouse 
model used here. Additional efficacy is expected in humans 
through RG7116-mediated ADCC. RG7116 binds with 
high affinity to the FcRγIIIa receptor found on ADCC-
competent cells such as macrophages and natural killer 
(NK) cells (absent in the SCID-beige mice used in these 
studies) and significantly enhances in vitro ADCC com-
pared to non-glycoengineered RG7116 [22]. RG7116-
mediated cell killing may also help suppress the develop-
ment of resistance to HER3 signaling inhibition. Assessing 
the ADCC potential of novel humanized mAbs in animal 
models is challenging, as this requires the presence of 
immune effector cells (i.e., immunocompetent mice) and 
also that the human mAb interacts with the receptors on 
these cells. A SCID–human FcγRIIIa transgenic mouse 
model (which bears murine FcγRIV-positive macrophages 
and human FcγRIIIa-positive transgenic murine NK cells) 
was recently used to demonstrate the ADCC activity of 
imgatuzumab, which is glycoengineered in the same way as 
RG7116 [28]. A NOD/SCID/gamma c(null) mouse model, 
which is receptive to the administration of human NK cells, 
has also been developed to specifically investigate NK cell-
mediated ADCC [29]. Further evaluation of RG7116 in 
models such as these is clearly warranted to investigate the 
contribution of RG7116-mediated ADCC to its efficacy.
RG7116-induced effects on HER3 and pHER3 levels 
were also seen in the skin and oral mucosa of a cynomol-
gus monkey, suggesting that these may be useful surrogate 
tissues for PD evaluation of RG7116 in early develop-
ment clinical trials. Initial data from a first-in-human trial 
of RG7116 have shown that downregulation of membrane 
HER3 is also seen in skin samples of patients with HER3-
positive epithelial tumors treated with RG7116 (at a dose of 
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100 mg and above), and this was associated with downreg-
ulation of HER3 in on-treatment tumor samples (at 200 mg 
and above) [30]. Skin biopsies have been used as a surro-
gate tissue for monitoring the effects of anti-HER1 thera-
pies [31–34]. The value of this approach has been shown 
for erlotinib, where suppression of HER1 phosphorylation 
in the skin of patients with head and neck cancer was cor-
related with increased survival [35].
While these studies were not designed to address differ-
ences among baseline tumor volumes, response, and dose/
exposure, we analyzed different mice representing animals 
with the smallest and highest tumor volume at baseline 
from each of the multiple dosing studies in an attempt to 
understand the variability in anti-tumor activity observed 
primarily in mice treated with the lowest dose (0.3 mg/kg). 
This dose was efficacious in animals with smallest baseline 
tumor volumes, but not in animals with larger tumors. The 
efficacy observed was consistent with the Cmin accumula-
tion observed in the mouse with the smallest tumor vol-
ume compared to no RG7116 accumulation observed in 
the mouse with the largest tumor volume. Such a finding 
might indicate that baseline tumor characteristics affect the 
efficacy of RG7116 at a given dose. Similar findings have 
been reported with the anti-CD20 mAb rituximab, where 
baseline tumor burden was correlated with survival in 
mice treated at the same dose [36]. Notably, size-matched 
FaDu tumor-bearing mice belonging to the vehicle group 
displayed progressive growth independent of their baseline 
size. However, further work will be required to properly 
explore the association between tumor volume, response, 
and dose for the RG7116 molecule.
In summary, RG7116 demonstrated strong dose-depend-
ent tumor growth inhibition in a rapidly growing FaDu xen-
ograft model of human cancer. Promising preclinical effi-
cacy was demonstrated, and target modulation of pHER3 
and HER3 was observed following weekly administration 
and with administration once every 3 weeks. These stud-
ies highlight the value of investigating pharmacokinetic 
behavior and measuring total HER3 or pHER3/HER3 ratio 
in tumor, and the value of skin biopsies as potential sur-
rogate markers for efficacy and guiding optimal dosing in 
the clinic.
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